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background:  Percutaneous Coronary Intervention is the current treatment of choice in patients with acute ST-elevation Myocardial Infarction 
(STEMI). The current guidelines recommend culprit vessel revascularization (CVR) in patients with STEMI and multivessel disease without cardiogenic 
shock. We performed a meta-analysis of all Randomized Controlled Trials (RCTs) comparing multivessel revascularization (MVR) with CVR or staged 
revascularization (SR) in patients with acute STEMI. 
methods: We searched PubMed, Cochrane Database and EMBASE from 1985 to September 2013 for the RCTs that compared the MVR with the 
CVR/SR in patients with STEMI. Random Effects Model was used for the analysis. Heterogeneity among the study effects was measured with I2 
statistics. 
results: We identified a total of 4 RCTs with 842 patients. MVR, in comparison to CVR/SR significantly lowered Major Adverse Cardiovascular 
Events (MACE) - a composite of death, MI and revascularization (Odds ratio: 0.438, CI: 0.303-0.632, p-value <0.001, I2: 0). MVR also significantly 
reduced MI (Odds Ratio: 0.385, CI: 0.198-0.749, p <0.05, I2: 0) and revascularization (Odds ratio: 0.449, CI: 0.299-0.674, p <0.001, I2: 25.9). 
However, total all-cause mortality was similar (OR: 0.669, CI: 0.365-1.227, p: 0.194, I2: 0). 
Conclusions: MVR is superior to CVR/SR in lowering MI and revascularization in patients with STEMI and multivessel disease.
